Corcept Therapeutics (CORT) Financials

$67.43 -1.19 (-1.73%)

As of 04/14/2025 04:00 PM Eastern

Annual Income Statements for Corcept Therapeutics

This table shows Corcept Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-6.41	8.14	129	75	94	106	113	101	105	140
Consolidated Net Income / (Loss)	-6.41	8.14	129	75	94	106	113	101	106	141
Net Income / (Loss) Continuing Operations	-6.41	8.14	129	75	94	106	113	101	106	141
Total Pre-Tax Income	-6.41	8.14	53	92	117	132	125	116	125	161
Total Operating Income	-3.44	10	53	89	112	128	124	113	107	137
Total Gross Profit	49	79	156	246	301	348	361	396	476	664
Total Revenue	50	81	159	251	306	354	366	402	482	675
Operating Revenue	50	81	159	251	306	354	366	402	482	675
Total Cost of Revenue	1.36	2.06	3.55	5.22	5.50	5.58	5.28	5.39	6.48	11
Operating Cost of Revenue	1.36	2.06	3.55	5.22	5.50	5.58	5.28	5.39	6.48	11
Total Operating Expenses	52	69	103	157	189	220	236	284	369	527
Selling, General & Admin Expense	37	45	62	81	100	105	122	153	184	280
Research & Development Expense	15	24	40	75	89	115	114	131	184	247
Other Special Charges / (Income)	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00
Total Other Income / (Expense), net	-2.97	-2.04	-0.05	2.66	5.07	3.40	0.53	3.56	17	25
Income Tax Expense	0.00	0.00	-76	17	22	26	12	15	18	20
Basic Earnings per Share	($0.06)	$0.07	$1.14	$0.65	$0.82	$0.92	$0.97	$0.95	$1.02	$1.35
Weighted Average Basic Shares Outstanding	106.88M	110.57M	113.53M	115.34M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M
Diluted Earnings per Share	($0.06)	$0.07	$1.04	$0.60	$0.77	$0.85	$0.89	$0.87	$0.94	$1.23
Weighted Average Diluted Shares Outstanding	106.88M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M
Weighted Average Basic & Diluted Shares Outstanding	106.80M	116.30M	113.30M	116M	114.90M	117.31M	105.96M	107.90M	103.52M	105.50M

This table shows Corcept Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	35	16	16	27	31	31	28	35	47	30
Consolidated Net Income / (Loss)	35	17	16	28	31	31	28	35	47	31
Net Income / (Loss) Continuing Operations	35	17	16	28	31	31	28	35	47	31
Total Pre-Tax Income	33	24	18	33	36	37	35	42	53	32
Total Operating Income	32	22	15	30	31	32	30	36	47	25
Total Gross Profit	100	102	104	116	122	134	144	161	180	179
Total Revenue	102	103	106	118	124	135	147	164	183	182
Operating Revenue	102	103	106	118	124	135	147	164	183	182
Total Cost of Revenue	1.34	1.48	1.39	1.57	1.65	1.88	2.54	2.52	2.87	2.96
Operating Cost of Revenue	1.34	1.48	1.39	1.57	1.65	1.88	2.54	2.52	2.87	2.96
Total Operating Expenses	68	79	89	87	91	102	115	126	133	154
Selling, General & Admin Expense	35	42	49	43	45	47	56	67	74	83
Research & Development Expense	33	37	41	43	46	55	59	59	59	70
Total Other Income / (Expense), net	1.07	1.78	3.58	3.35	5.21	5.14	5.49	6.00	6.35	6.70
Income Tax Expense	-1.60	7.68	2.56	5.40	5.01	5.45	7.23	6.11	5.73	1.22
Basic Earnings per Share	$0.32	$0.15	$0.15	$0.27	$0.31	$0.29	$0.27	$0.34	$0.45	$0.29
Weighted Average Basic Shares Outstanding	107.13M	106.79M	107.89M	101.96M	102.01M	103.56M	102.79M	103.12M	103.37M	103.23M
Diluted Earnings per Share	$0.30	$0.13	$0.14	$0.25	$0.28	$0.27	$0.25	$0.32	$0.41	$0.25
Weighted Average Diluted Shares Outstanding	116.62M	115.97M	115.43M	109.59M	111.10M	111.74M	109.92M	111.24M	113.72M	113.48M
Weighted Average Basic & Diluted Shares Outstanding	107.65M	107.90M	101.58M	102.55M	103.08M	103.52M	104.11M	104.49M	104.78M	105.50M

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	16	11	-20	11	-10	45	1.43	-11	69	-7.89
Net Cash From Operating Activities	3.13	18	61	116	136	152	168	120	127	198
Net Cash From Continuing Operating Activities	3.13	18	61	116	136	152	168	120	127	198
Net Income / (Loss) Continuing Operations	-6.41	8.14	129	75	94	106	113	101	106	141
Consolidated Net Income / (Loss)	-6.41	8.14	129	75	94	106	113	101	106	141
Depreciation Expense	0.16	0.09	0.11	0.24	0.70	0.53	1.07	1.26	1.04	0.80
Amortization Expense	0.02	0.02	0.01	-1.72	-0.27	3.02	7.49	3.57	-7.81	-10
Non-Cash Adjustments To Reconcile Net Income	8.86	8.99	14	24	28	39	40	42	54	74
Changes in Operating Assets and Liabilities, net	0.50	1.16	-82	18	14	3.19	7.17	-28	-27	-7.62
Net Cash From Investing Activities	-0.02	-0.19	-73	-91	-118	-119	136	-114	91	-178
Net Cash From Continuing Investing Activities	-0.02	-0.19	-73	-91	-118	-119	136	-114	91	-178
Purchase of Property, Plant & Equipment	-0.02	-0.19	-0.42	-0.30	-1.09	-1.24	-0.47	-0.41	-0.14	-2.17
Purchase of Investments	0.00	0.00	-103	-233	-299	-420	-313	-355	-329	-588
Sale and/or Maturity of Investments	-	0.00	30	143	182	302	449	241	420	413
Net Cash From Financing Activities	13	-7.10	-7.95	-14	-29	12	-303	-17	-149	-28
Net Cash From Continuing Financing Activities	13	-7.10	-7.95	-14	-29	12	-303	-17	-149	-28
Repurchase of Preferred Equity	-	-	-	-	-	-	-	0.00	-145	0.00
Repurchase of Common Equity	-	0.00	0.00	-24	-31	-9.95	-296	0.00	0.00	-16
Issuance of Common Equity	-	7.68	7.18	9.32	8.42	23	16	4.38	5.81	9.62
Other Financing Activities, net	22	-	0.00	0.00	-6.09	-1.07	-23	-22	-9.11	-22
Cash Income Taxes Paid	0.06	0.04	0.38	1.35	6.74	11	9.10	40	48	60

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	15	16	234	-128	-61	24	14	-21	8.70	-9.62
Net Cash From Operating Activities	34	33	26	42	53	5.89	24	41	74	59
Net Cash From Continuing Operating Activities	34	33	26	42	53	5.89	24	41	74	59
Net Income / (Loss) Continuing Operations	35	17	16	28	31	31	28	35	47	31
Consolidated Net Income / (Loss)	35	17	16	28	31	31	28	35	47	31
Depreciation Expense	0.20	0.66	0.17	0.42	0.23	0.21	0.07	0.13	0.32	0.28
Amortization Expense	0.81	-0.17	0.69	0.52	-5.88	-3.14	0.11	0.07	0.18	-11
Non-Cash Adjustments To Reconcile Net Income	11	9.12	9.05	14	19	13	-0.19	9.30	19	46
Changes in Operating Assets and Liabilities, net	-12	7.18	0.17	0.15	8.49	-36	-3.99	-3.81	6.98	-6.79
Net Cash From Investing Activities	-4.79	-17	207	-24	-110	17	-9.01	-60	-44	-64
Net Cash From Continuing Investing Activities	-4.79	-17	207	-24	-110	17	-9.01	-60	-44	-64
Purchase of Property, Plant & Equipment	-0.35	-0.03	-	-	-0.04	-	-	-	-1.64	-0.12
Purchase of Investments	-79	-97	0.00	-89	-210	-30	-78	-143	-223	-145
Sale and/or Maturity of Investments	74	79	207	65	100	47	69	83	181	80
Net Cash From Financing Activities	-14	-0.06	0.18	-146	-3.92	0.77	-0.54	-2.15	-21	-4.56
Net Cash From Continuing Financing Activities	-14	-0.06	0.18	-146	-3.92	0.77	-0.54	-2.15	-21	-4.56
Issuance of Common Equity	1.66	0.79	1.41	1.50	1.14	1.76	1.69	3.24	2.27	2.42
Other Financing Activities, net	-16	-0.85	-1.23	-1.82	-5.06	-1.00	-1.76	-1.91	-12	-6.99

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	52	69	221	312	412	572	424	583	622	841
Total Current Assets	49	66	124	237	307	479	266	499	459	472
Cash & Equivalents	40	52	31	42	31	76	78	66	136	128
Short-Term Investments	-	0.00	58	165	245	365	146	365	233	256
Accounts Receivable	6.22	9.86	28	18	20	26	28	31	41	54
Inventories, net	1.68	2.33	4.58	4.73	5.42	4.91	4.99	6.10	7.73	12
Prepaid Expenses	0.64	1.96	2.67	7.74	6.04	6.70	10	16	28	22
Other Current Assets	-	-	-	-	-	-	0.00	14	14	0.00
Plant, Property, & Equipment, net	0.10	0.21	0.52	0.66	1.05	1.68	1.00	0.63	0.20	2.69
Total Noncurrent Assets	2.82	2.86	96	74	104	92	156	84	163	366
Long-Term Investments	-	0.00	15	0.00	39	36	112	4.95	57	220
Noncurrent Deferred & Refundable Income Taxes	-	0.00	77	63	46	32	27	61	91	131
Other Noncurrent Operating Assets	2.82	2.86	3.85	12	19	24	17	17	15	16
Total Liabilities & Shareholders' Equity	52	69	221	312	412	572	424	583	622	841
Total Liabilities	33	27	30	36	41	48	48	82	115	161
Total Current Liabilities	21	27	30	36	39	47	48	72	105	141
Accounts Payable	1.33	2.29	8.58	8.27	7.54	11	6.91	12	17	15
Accrued Expenses	4.43	10	21	27	30	35	40	59	87	125
Other Current Liabilities	-	-	-	0.00	1.56	2.05	0.53	1.14	0.15	0.83
Total Noncurrent Liabilities	13	0.00	0.00	0.24	2.29	0.90	0.41	9.10	10	20
Noncurrent Deferred Revenue	-	-	0.00	0.24	0.39	0.40	0.41	9.10	10	14
Other Noncurrent Operating Liabilities	-	-	-	0.00	1.90	0.50	-	-	0.00	6.11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	18	41	191	276	371	523	376	502	507	680
Total Preferred & Common Equity	18	41	191	276	371	523	376	502	507	680
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	18	41	191	276	371	523	376	502	507	680
Common Stock	349	364	384	417	457	516	591	662	739	832
Retained Earnings	-330	-322	-193	-118	-24	82	195	296	403	544
Treasury Stock	-	-	0.00	-24	-63	-76	-410	-456	-635	-696
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.08	-0.07	0.26	0.42	-0.23	-0.87	0.61	-0.22

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	533	618	525	594	656	715	784
Total Current Assets	452	534	433	432	503	561	467
Cash & Equivalents	50	300	172	112	150	129	137
Short-Term Investments	346	165	191	243	261	345	243
Accounts Receivable	29	33	33	35	62	54	60
Inventories, net	6.05	6.41	6.92	7.51	7.19	8.35	8.05
Prepaid Expenses	21	16	16	20	24	26	19
Other Current Assets	-	14	14	14	0.00	0.00	0.00
Plant, Property, & Equipment, net	0.80	0.46	0.41	0.30	0.13	1.47	2.93
Total Noncurrent Assets	80	83	92	162	152	152	314
Long-Term Investments	4.90	0.00	0.00	60	40	19	167
Noncurrent Deferred & Refundable Income Taxes	57	68	78	87	98	112	127
Other Noncurrent Operating Assets	18	15	13	15	14	21	20
Total Liabilities & Shareholders' Equity	533	618	525	594	656	715	784
Total Liabilities	60	88	103	132	108	118	145
Total Current Liabilities	53	79	93	122	97	101	126
Accounts Payable	8.18	11	7.98	17	13	19	19
Accrued Expenses	43	67	85	105	85	81	107
Other Current Liabilities	1.71	0.58	0.30	0.23	0.08	0.04	0.43
Total Noncurrent Liabilities	6.82	9.40	9.95	10	11	18	19
Noncurrent Deferred Revenue	6.82	9.40	9.95	10	11	12	13
Other Noncurrent Operating Liabilities	-	-	-	-	-	5.63	6.36
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	473	530	422	462	548	596	639
Total Preferred & Common Equity	473	530	422	462	548	596	639
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	473	530	422	462	548	596	639
Common Stock	649	680	696	723	758	781	806
Retained Earnings	280	312	340	371	430	466	513
Treasury Stock	-	-463	-	-	-641	-	-682
Accumulated Other Comprehensive Income / (Loss)	-2.38	-0.15	0.05	-0.23	0.26	0.08	1.57

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	89.39%	61.72%	95.77%	57.82%	21.99%	15.46%	3.42%	9.80%	20.04%	39.94%
EBITDA Growth	77.30%	232.37%	541.68%	71.31%	29.16%	15.40%	-1.17%	-12.06%	-14.43%	26.70%
EBIT Growth	76.80%	227.03%	548.72%	74.51%	26.61%	12.79%	-5.01%	-9.90%	-4.75%	27.66%
NOPAT Growth	87.53%	522.35%	1,169.69%	-43.33%	23.01%	14.63%	8.49%	-12.25%	-7.01%	30.99%
Net Income Growth	79.58%	227.03%	1,486.27%	-41.60%	24.89%	12.56%	6.13%	-9.86%	4.66%	33.04%
EPS Growth	80.65%	216.67%	1,385.71%	-42.31%	28.33%	10.39%	4.71%	-2.25%	8.05%	30.85%
Operating Cash Flow Growth	111.43%	487.57%	231.33%	89.82%	17.68%	11.65%	10.48%	-28.33%	5.58%	55.91%
Free Cash Flow Firm Growth	92.96%	754.66%	316.87%	94.54%	13.49%	9.05%	5.14%	-38.32%	3.08%	65.44%
Invested Capital Growth	-11.12%	-18.88%	1,829.07%	-20.50%	-19.17%	-16.86%	-13.89%	63.08%	24.66%	-6.01%
Revenue Q/Q Growth	13.43%	12.20%	22.72%	5.70%	7.38%	-0.61%	3.71%	1.06%	7.19%	7.40%
EBITDA Q/Q Growth	21.92%	18.83%	45.97%	2.67%	9.75%	-3.17%	5.49%	-12.10%	6.08%	-9.88%
EBIT Q/Q Growth	21.57%	19.30%	46.01%	4.60%	9.91%	-4.12%	4.98%	-11.17%	9.35%	-4.47%
NOPAT Q/Q Growth	57.86%	49.19%	258.67%	-50.73%	8.55%	-2.36%	5.92%	-14.65%	14.22%	-2.03%
Net Income Q/Q Growth	43.10%	80.81%	264.86%	-50.30%	8.49%	-3.10%	5.69%	-13.17%	16.05%	-0.43%
EPS Q/Q Growth	50.00%	40.00%	258.62%	-50.41%	6.94%	-3.41%	7.23%	-13.00%	17.50%	-1.60%
Operating Cash Flow Q/Q Growth	228.49%	2.26%	50.01%	-2.83%	24.67%	-8.09%	9.35%	-11.76%	-17.80%	36.92%
Free Cash Flow Firm Q/Q Growth	70.59%	-1.36%	64.22%	-4.55%	31.84%	-11.81%	11.58%	-16.98%	-28.53%	60.06%
Invested Capital Q/Q Growth	-16.66%	113.91%	802.09%	9.94%	-17.21%	2.16%	-11.23%	-9.67%	73.61%	-16.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.29%	97.47%	97.77%	97.92%	98.20%	98.42%	98.56%	98.66%	98.66%	98.39%
EBITDA Margin	-12.39%	10.14%	33.24%	36.09%	38.21%	38.19%	36.50%	29.23%	20.84%	18.87%
Operating Margin	-6.85%	12.52%	33.20%	35.62%	36.41%	36.23%	34.01%	28.03%	22.24%	20.29%
EBIT Margin	-12.74%	10.01%	33.17%	36.68%	38.07%	37.19%	34.16%	28.03%	22.24%	20.29%
Profit (Net Income) Margin	-12.74%	10.01%	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22.00%	20.92%
Tax Burden Percent	100.00%	100.00%	244.52%	81.83%	80.72%	80.55%	90.01%	87.29%	85.21%	87.44%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	103.16%	116.10%	117.92%
Effective Tax Rate	0.00%	0.00%	-144.52%	18.17%	19.28%	19.45%	9.99%	12.71%	14.79%	12.56%
Return on Invested Capital (ROIC)	-40.82%	202.31%	282.65%	93.85%	144.15%	201.87%	259.22%	186.88%	124.78%	151.84%
ROIC Less NNEP Spread (ROIC-NNEP)	201.25%	210.49%	282.82%	92.45%	142.59%	201.18%	259.11%	186.07%	121.36%	147.67%
Return on Net Nonoperating Assets (RNNOA)	-43.99%	-175.12%	-171.50%	-61.55%	-115.04%	-178.17%	-234.20%	-163.77%	-103.73%	-128.03%
Return on Equity (ROE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.70%	25.03%	23.11%	21.05%	23.81%
Cash Return on Invested Capital (CROIC)	-29.05%	223.15%	102.36%	116.69%	165.36%	220.29%	274.15%	138.92%	102.82%	158.03%
Operating Return on Assets (OROA)	-14.81%	13.49%	36.51%	34.63%	32.23%	26.75%	25.11%	22.37%	17.81%	18.73%
Return on Assets (ROA)	-14.81%	13.49%	89.27%	28.34%	26.02%	21.55%	22.60%	20.14%	17.62%	19.32%
Return on Common Equity (ROCE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.70%	25.03%	23.11%	21.05%	23.81%
Return on Equity Simple (ROE_SIMPLE)	-34.64%	19.67%	67.61%	27.33%	25.37%	20.26%	29.94%	20.21%	20.95%	20.78%
Net Operating Profit after Tax (NOPAT)	-2.41	10	129	73	90	103	112	98	91	120
NOPAT Margin	-4.79%	12.52%	81.18%	29.15%	29.39%	29.18%	30.61%	24.46%	18.95%	17.74%
Net Nonoperating Expense Percent (NNEP)	-242.08%	-8.19%	-0.17%	1.40%	1.57%	0.69%	0.12%	0.80%	3.42%	4.17%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	19.59%	18.04%	17.62%
Cost of Revenue to Revenue	2.71%	2.53%	2.23%	2.08%	1.80%	1.58%	1.44%	1.34%	1.34%	1.61%
SG&A Expenses to Revenue	73.48%	55.63%	39.21%	32.35%	32.75%	29.76%	33.43%	38.04%	38.20%	41.53%
R&D to Revenue	30.66%	29.32%	25.36%	29.95%	29.04%	32.43%	31.11%	32.60%	38.22%	36.57%
Operating Expenses to Revenue	104.14%	84.95%	64.57%	62.30%	61.79%	62.19%	64.54%	70.63%	76.42%	78.10%
Earnings before Interest and Taxes (EBIT)	-6.41	8.14	53	92	117	132	125	113	107	137
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.23	8.25	53	91	117	135	134	117	101	127
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	29.28	19.48	10.79	5.59	3.73	5.81	6.08	4.36	6.61	7.77
Price to Tangible Book Value (P/TBV)	29.28	19.48	10.79	5.59	3.73	5.81	6.08	4.36	6.61	7.77
Price to Revenue (P/Rev)	10.77	9.91	12.95	6.14	4.51	8.59	6.25	5.44	6.94	7.82
Price to Earnings (P/E)	0.00	99.03	15.96	20.46	14.68	28.67	20.32	21.59	31.74	37.78
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.01%	6.26%	4.89%	6.81%	3.49%	4.92%	4.63%	3.15%	2.65%
Enterprise Value to Invested Capital (EV/IC)	95.17	170.67	22.51	19.33	19.11	55.17	48.76	26.83	35.95	61.19
Enterprise Value to Revenue (EV/Rev)	10.52	9.46	12.29	5.32	3.48	7.24	5.33	4.35	6.06	6.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	93.26	36.98	14.73	9.12	18.96	14.60	14.90	29.08	36.72
Enterprise Value to EBIT (EV/EBIT)	0.00	94.50	37.06	14.50	9.15	19.47	15.60	15.53	27.24	34.15
Enterprise Value to NOPAT (EV/NOPAT)	0.00	75.57	15.14	18.24	11.85	24.81	17.41	17.80	31.97	39.05
Enterprise Value to Operating Cash Flow (EV/OCF)	168.93	41.83	32.12	11.55	7.84	16.86	11.62	14.54	23.01	23.61
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	68.51	41.81	14.67	10.33	22.74	16.46	23.94	38.80	37.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.49	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.22	-0.83	-0.61	-0.67	-0.81	-0.89	-0.90	-0.88	-0.85	-0.87
Leverage Ratio	5.73	2.02	1.25	1.14	1.12	1.10	1.11	1.15	1.19	1.23
Compound Leverage Factor	5.73	2.02	1.25	1.14	1.12	1.10	1.11	1.18	1.39	1.45
Debt to Total Capital	59.78%	26.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	32.54%	26.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	27.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	40.22%	73.83%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-4.41	1.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	2.08	-4.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-2.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-11.41	1.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	5.37	-3.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-5.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.03	13.35	42.62	27.87	22.55	40.17	31.71	18.99	20.43	22.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.35	2.40	4.20	6.66	7.91	10.08	5.60	6.89	4.39	3.35
Quick Ratio	2.23	2.24	3.95	6.31	7.62	9.83	5.28	6.38	3.92	3.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.72	11	47	91	103	113	118	73	75	125
Operating Cash Flow to CapEx	18,411.76%	9,479.90%	14,542.96%	38,813.76%	12,510.75%	12,275.44%	35,797.87%	29,133.90%	91,394.96%	9,119.11%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.16	1.35	1.10	0.94	0.85	0.72	0.74	0.80	0.80	0.92
Accounts Receivable Turnover	10.53	10.11	8.37	10.98	16.34	15.34	13.60	13.70	13.37	14.20
Inventory Turnover	0.94	1.03	1.03	1.12	1.08	1.08	1.07	0.97	0.94	1.08
Fixed Asset Turnover	301.11	536.77	440.39	428.38	359.51	259.72	273.42	491.57	1,165.16	468.13
Accounts Payable Turnover	0.85	1.14	0.65	0.62	0.70	0.62	0.60	0.57	0.44	0.66
Days Sales Outstanding (DSO)	34.68	36.09	43.63	33.26	22.34	23.79	26.84	26.65	27.31	25.71
Days Inventory Outstanding (DIO)	387.39	355.69	354.58	325.74	336.75	337.86	342.05	375.78	389.44	337.80
Days Payable Outstanding (DPO)	430.57	320.57	558.13	589.49	523.99	591.47	603.45	639.99	827.09	549.61
Cash Conversion Cycle (CCC)	-8.50	71.21	-159.93	-230.50	-164.90	-229.82	-234.56	-237.56	-410.34	-186.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5.56	4.51	87	69	56	46	40	65	81	76
Invested Capital Turnover	8.52	16.16	3.48	3.22	4.90	6.92	8.47	7.64	6.58	8.56
Increase / (Decrease) in Invested Capital	-0.70	-1.05	82	-18	-13	-9.42	-6.45	25	16	-4.88
Enterprise Value (EV)	529	769	1,957	1,336	1,067	2,562	1,950	1,750	2,923	4,676
Market Capitalization	542	806	2,061	1,543	1,383	3,039	2,286	2,186	3,348	5,280
Book Value per Share	$0.17	$0.37	$1.67	$2.39	$3.25	$4.50	$3.25	$4.66	$4.92	$6.49
Tangible Book Value per Share	$0.17	$0.37	$1.67	$2.39	$3.25	$4.50	$3.25	$4.66	$4.92	$6.49
Total Capital	46	56	191	276	371	523	376	502	507	680
Total Debt	27	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-13	-37	-104	-207	-315	-477	-336	-437	-425	-603
Capital Expenditures (CapEx)	0.02	0.19	0.42	0.30	1.09	1.24	0.47	0.41	0.14	2.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.63	1.44	5.87	-5.51	-7.45	-9.69	-4.61	-4.91	-14	-53
Debt-free Net Working Capital (DFNWC)	43	53	95	201	269	431	219	427	354	331
Net Working Capital (NWC)	28	38	95	201	269	431	219	427	354	331
Net Nonoperating Expense (NNE)	4.00	2.04	0.12	-2.17	-4.09	-2.74	-0.48	-3.10	-15	-21
Net Nonoperating Obligations (NNO)	-13	-37	-104	-207	-315	-477	-336	-437	-425	-603
Total Depreciation and Amortization (D&A)	0.18	0.11	0.12	-1.49	0.43	3.54	8.56	4.83	-6.77	-9.60
Debt-free, Cash-free Net Working Capital to Revenue	5.24%	1.77%	3.69%	-2.19%	-2.43%	-2.74%	-1.26%	-1.22%	-2.92%	-7.78%
Debt-free Net Working Capital to Revenue	85.65%	65.15%	59.43%	80.10%	87.61%	121.80%	59.82%	106.20%	73.41%	49.01%
Net Working Capital to Revenue	55.89%	47.12%	59.43%	80.10%	87.61%	121.80%	59.82%	106.20%	73.41%	49.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	$0.07	$1.14	$0.65	$0.82	$0.92	$0.97	$0.95	$1.02	$1.35
Adjusted Weighted Average Basic Shares Outstanding	109.66M	110.57M	113.53M	115.34M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M
Adjusted Diluted Earnings per Share	($0.06)	$0.07	$1.04	$0.60	$0.77	$0.85	$0.89	$0.87	$0.94	$1.23
Adjusted Weighted Average Diluted Shares Outstanding	109.66M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M
Adjusted Basic & Diluted Earnings per Share	($0.06)	$0.07	$0.00	$0.00	$0.82	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.88M	112.94M	114.83M	114.72M	114.59M	117.31M	105.96M	107.90M	103.52M	105.50M
Normalized Net Operating Profit after Tax (NOPAT)	-2.41	7.13	37	73	90	103	112	98	91	120
Normalized NOPAT Margin	-4.79%	8.76%	23.24%	29.15%	29.39%	29.18%	30.61%	24.46%	18.95%	17.74%
Pre Tax Income Margin	-12.74%	10.01%	33.17%	36.68%	38.07%	37.19%	34.16%	28.91%	25.82%	23.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	31.37%	32.89%	9.38%	263.07%	0.00%	0.00%	11.09%

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.82%	4.28%	12.77%	13.86%	21.50%	31.39%	38.95%	39.15%	47.69%	34.33%
EBITDA Growth	-19.63%	-41.39%	-45.36%	-7.12%	-22.48%	25.06%	88.89%	17.25%	84.46%	-48.57%
EBIT Growth	-12.04%	-38.75%	-44.68%	-5.88%	-2.37%	40.76%	98.61%	20.31%	49.46%	-20.23%
NOPAT Growth	10.11%	-51.90%	-43.71%	-7.98%	-19.71%	75.34%	82.93%	22.79%	54.56%	-9.92%
Net Income Growth	13.39%	-47.98%	-30.35%	0.47%	-9.18%	88.06%	74.83%	28.92%	50.47%	-1.94%
EPS Growth	25.00%	-50.00%	-30.00%	4.17%	-6.67%	107.69%	78.57%	28.00%	46.43%	-7.41%
Operating Cash Flow Growth	-30.91%	-32.45%	-26.36%	134.40%	57.24%	-82.37%	-8.48%	-2.61%	39.54%	907.30%
Free Cash Flow Firm Growth	-79.45%	-125.61%	-130.79%	52.22%	725.34%	210.66%	25.96%	-156.32%	-105.36%	167.94%
Invested Capital Growth	60.27%	63.08%	62.46%	-3.31%	-35.14%	24.66%	50.06%	77.84%	94.71%	-6.01%
Revenue Q/Q Growth	-1.60%	1.31%	2.52%	11.42%	5.00%	9.55%	8.42%	11.57%	11.45%	-0.36%
EBITDA Q/Q Growth	0.22%	-30.22%	-31.64%	94.28%	-16.35%	12.58%	1.98%	20.59%	31.59%	-68.61%
EBIT Q/Q Growth	1.60%	-29.55%	-33.98%	99.17%	5.39%	1.58%	-6.85%	20.65%	30.92%	-45.79%
NOPAT Q/Q Growth	24.61%	-54.05%	-16.84%	93.29%	8.72%	0.34%	-13.25%	29.75%	36.85%	-41.52%
Net Income Q/Q Growth	26.10%	-51.74%	-4.76%	73.36%	13.99%	-0.07%	-12.04%	27.83%	33.04%	-34.88%
EPS Q/Q Growth	25.00%	-56.67%	7.69%	78.57%	12.00%	-3.57%	-7.41%	28.00%	28.13%	-39.02%
Operating Cash Flow Q/Q Growth	86.52%	-0.77%	-22.26%	62.91%	25.12%	-88.87%	303.53%	73.35%	79.27%	-19.68%
Free Cash Flow Firm Q/Q Growth	-63.94%	-255.45%	-22.06%	322.46%	95.53%	-79.16%	-181.67%	-69.23%	81.39%	1,141.83%
Invested Capital Q/Q Growth	19.65%	-9.67%	-1.07%	-9.57%	-19.74%	73.61%	19.09%	7.17%	-12.13%	-16.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.68%	98.56%	98.69%	98.66%	98.67%	98.61%	98.27%	98.46%	98.43%	98.37%
EBITDA Margin	32.38%	22.30%	14.87%	25.93%	20.66%	21.23%	20.22%	21.85%	25.80%	8.13%
Operating Margin	31.39%	21.83%	14.06%	25.13%	25.22%	23.39%	20.09%	21.73%	25.53%	13.89%
EBIT Margin	31.39%	21.83%	14.06%	25.13%	25.22%	23.39%	20.09%	21.73%	25.53%	13.89%
Profit (Net Income) Margin	33.96%	16.18%	15.03%	23.39%	25.39%	23.16%	18.91%	21.67%	25.86%	16.90%
Tax Burden Percent	104.68%	68.68%	86.14%	83.60%	86.24%	85.19%	79.34%	85.32%	89.18%	96.20%
Interest Burden Percent	103.35%	107.90%	124.11%	111.31%	116.70%	116.23%	118.62%	116.87%	113.62%	126.52%
Effective Tax Rate	-4.86%	31.62%	13.86%	16.40%	13.76%	14.81%	20.66%	14.68%	10.82%	3.80%
Return on Invested Capital (ROIC)	223.24%	114.04%	96.14%	151.55%	164.47%	131.17%	103.45%	130.27%	207.34%	114.35%
ROIC Less NNEP Spread (ROIC-NNEP)	223.00%	113.71%	95.40%	150.80%	163.37%	130.16%	102.50%	129.07%	206.16%	113.10%
Return on Net Nonoperating Assets (RNNOA)	-197.21%	-100.08%	-84.79%	-130.08%	-142.57%	-111.25%	-87.15%	-108.51%	-180.30%	-98.06%
Return on Equity (ROE)	26.04%	13.97%	11.35%	21.47%	21.90%	19.93%	16.30%	21.76%	27.03%	16.29%
Cash Return on Invested Capital (CROIC)	150.15%	138.92%	121.83%	148.44%	177.10%	102.82%	86.36%	76.72%	112.84%	158.03%
Operating Return on Assets (OROA)	22.32%	17.42%	10.71%	21.08%	20.14%	18.73%	16.52%	19.98%	23.28%	12.82%
Return on Assets (ROA)	24.14%	12.91%	11.45%	19.61%	20.27%	18.54%	15.54%	19.92%	23.59%	15.61%
Return on Common Equity (ROCE)	26.04%	13.97%	11.35%	21.47%	21.90%	19.93%	16.30%	21.76%	27.03%	16.29%
Return on Equity Simple (ROE_SIMPLE)	24.67%	0.00%	17.84%	22.44%	19.81%	0.00%	21.54%	21.13%	22.20%	0.00%
Net Operating Profit after Tax (NOPAT)	33	15	13	25	27	27	23	30	42	24
NOPAT Margin	32.92%	14.93%	12.11%	21.01%	21.75%	19.92%	15.94%	18.54%	22.76%	13.36%
Net Nonoperating Expense Percent (NNEP)	0.24%	0.33%	0.74%	0.75%	1.10%	1.02%	0.95%	1.20%	1.18%	1.25%
Return On Investment Capital (ROIC_SIMPLE)	-	3.07%	-	-	-	5.32%	-	-	-	3.58%
Cost of Revenue to Revenue	1.32%	1.44%	1.31%	1.34%	1.33%	1.39%	1.73%	1.54%	1.57%	1.63%
SG&A Expenses to Revenue	34.57%	41.07%	45.97%	36.77%	36.62%	34.82%	38.33%	40.86%	40.40%	45.84%
R&D to Revenue	32.73%	35.66%	38.66%	36.76%	36.83%	40.40%	39.85%	35.86%	32.50%	38.65%
Operating Expenses to Revenue	67.29%	76.73%	84.63%	73.53%	73.45%	75.23%	78.18%	76.73%	72.90%	84.49%
Earnings before Interest and Taxes (EBIT)	32	22	15	30	31	32	30	36	47	25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	33	23	16	31	26	29	30	36	47	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.80	4.36	4.41	5.36	6.05	6.61	4.74	5.67	7.57	7.77
Price to Tangible Book Value (P/TBV)	5.80	4.36	4.41	5.36	6.05	6.61	4.74	5.67	7.57	7.77
Price to Revenue (P/Rev)	6.91	5.44	5.65	5.28	6.21	6.94	4.96	5.94	7.69	7.82
Price to Earnings (P/E)	23.50	21.59	24.78	23.98	30.77	31.74	22.15	27.07	34.42	37.78
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.26%	4.63%	4.03%	4.17%	3.25%	3.15%	4.51%	3.69%	2.91%	2.65%
Enterprise Value to Invested Capital (EV/IC)	32.48	26.83	29.01	32.51	50.80	35.95	22.16	27.85	47.03	61.19
Enterprise Value to Revenue (EV/Rev)	5.90	4.35	4.52	4.43	5.29	6.06	4.10	5.07	6.82	6.93
Enterprise Value to EBITDA (EV/EBITDA)	17.55	14.90	17.91	18.57	25.11	29.08	18.74	24.14	30.35	36.72
Enterprise Value to EBIT (EV/EBIT)	18.49	15.53	18.59	19.19	24.25	27.24	17.60	22.59	29.91	34.15
Enterprise Value to NOPAT (EV/NOPAT)	20.36	17.80	21.20	22.03	29.72	31.97	21.04	26.86	35.09	39.05
Enterprise Value to Operating Cash Flow (EV/OCF)	17.20	14.54	16.86	14.02	15.39	23.01	17.19	23.36	29.65	23.61
Enterprise Value to Free Cash Flow (EV/FCFF)	26.64	23.94	29.48	21.53	22.57	38.80	30.79	46.47	55.07	37.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-0.88	-0.89	-0.86	-0.87	-0.85	-0.85	-0.84	-0.87	-0.87
Leverage Ratio	1.10	1.15	1.16	1.18	1.21	1.19	1.18	1.22	1.25	1.23
Compound Leverage Factor	1.14	1.24	1.44	1.32	1.41	1.39	1.40	1.42	1.42	1.56
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	30.09	18.48	18.23	15.85	15.10	20.03	17.02	19.80	22.39	21.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.52	6.89	6.77	4.65	3.54	4.39	5.18	5.57	3.70	3.35
Quick Ratio	8.02	6.38	6.31	4.25	3.20	3.92	4.86	5.23	3.49	3.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	6.33	-9.84	-12	27	52	11	-8.90	-15	-2.80	29
Operating Cash Flow to CapEx	9,586.32%	107,703.23%	0.00%	0.00%	142,997.30%	0.00%	0.00%	0.00%	4,515.54%	49,008.26%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.71	0.80	0.76	0.84	0.80	0.80	0.82	0.92	0.91	0.92
Accounts Receivable Turnover	14.22	13.70	13.86	14.10	14.05	13.37	11.13	13.19	13.32	14.20
Inventory Turnover	0.95	0.97	0.96	0.94	0.90	0.94	1.12	1.12	1.26	1.08
Fixed Asset Turnover	392.33	491.57	697.26	671.61	816.00	1,165.16	1,780.71	604.36	388.96	468.13
Accounts Payable Turnover	0.71	0.57	0.54	0.71	0.49	0.44	0.64	0.62	0.56	0.66
Days Sales Outstanding (DSO)	25.67	26.65	26.34	25.88	25.97	27.31	32.79	27.68	27.39	25.71
Days Inventory Outstanding (DIO)	383.11	375.78	379.74	390.07	406.66	389.44	325.27	324.69	289.76	337.80
Days Payable Outstanding (DPO)	511.37	639.99	677.14	512.29	746.44	827.09	568.62	584.09	657.13	549.61
Cash Conversion Cycle (CCC)	-102.59	-237.56	-271.06	-96.33	-313.81	-410.34	-210.56	-231.71	-339.97	-186.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	72	65	65	58	47	81	97	104	91	76
Invested Capital Turnover	6.78	7.64	7.94	7.21	7.56	6.58	6.49	7.03	9.11	8.56
Increase / (Decrease) in Invested Capital	27	25	25	-2.00	-25	16	32	45	44	-4.88
Enterprise Value (EV)	2,345	1,750	1,872	1,897	2,379	2,923	2,146	2,890	4,288	4,676
Market Capitalization	2,746	2,186	2,337	2,260	2,794	3,348	2,597	3,383	4,836	5,280
Book Value per Share	$4.42	$4.66	$4.91	$4.15	$4.50	$4.92	$5.33	$5.73	$6.11	$6.49
Tangible Book Value per Share	$4.42	$4.66	$4.91	$4.15	$4.50	$4.92	$5.33	$5.73	$6.11	$6.49
Total Capital	473	502	530	422	462	507	548	596	639	680
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-401	-437	-465	-363	-415	-425	-451	-492	-548	-603
Capital Expenditures (CapEx)	0.35	0.03	0.00	0.00	0.04	0.00	0.00	0.00	1.64	0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.07	-4.91	-10	-24	-46	-14	-4.60	-13	-40	-53
Debt-free Net Working Capital (DFNWC)	399	427	455	340	310	354	406	460	341	331
Net Working Capital (NWC)	399	427	455	340	310	354	406	460	341	331
Net Nonoperating Expense (NNE)	-1.06	-1.29	-3.08	-2.80	-4.49	-4.38	-4.36	-5.12	-5.66	-6.45
Net Nonoperating Obligations (NNO)	-401	-437	-465	-363	-415	-425	-451	-492	-548	-603
Total Depreciation and Amortization (D&A)	1.00	0.49	0.86	0.94	-5.64	-2.92	0.18	0.20	0.50	-10
Debt-free, Cash-free Net Working Capital to Revenue	0.77%	-1.22%	-2.42%	-5.54%	-10.13%	-2.92%	-0.88%	-2.29%	-6.30%	-7.78%
Debt-free Net Working Capital to Revenue	100.43%	106.20%	109.96%	79.30%	68.81%	73.41%	77.58%	80.77%	54.21%	49.01%
Net Working Capital to Revenue	100.43%	106.20%	109.96%	79.30%	68.81%	73.41%	77.58%	80.77%	54.21%	49.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.32	$0.15	$0.15	$0.27	$0.31	$0.29	$0.27	$0.34	$0.45	$0.29
Adjusted Weighted Average Basic Shares Outstanding	107.13M	106.79M	107.89M	101.96M	102.01M	103.56M	102.79M	103.12M	103.37M	103.23M
Adjusted Diluted Earnings per Share	$0.30	$0.13	$0.14	$0.25	$0.28	$0.27	$0.25	$0.32	$0.41	$0.25
Adjusted Weighted Average Diluted Shares Outstanding	116.62M	115.97M	115.43M	109.59M	111.10M	111.74M	109.92M	111.24M	113.72M	113.48M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	107.65M	107.90M	101.58M	102.55M	103.08M	103.52M	104.11M	104.49M	104.78M	105.50M
Normalized Net Operating Profit after Tax (NOPAT)	22	15	13	25	27	27	23	30	42	24
Normalized NOPAT Margin	21.97%	14.93%	12.11%	21.01%	21.75%	19.92%	15.94%	18.54%	22.76%	13.36%
Pre Tax Income Margin	32.44%	23.56%	17.45%	27.97%	29.44%	27.18%	23.84%	25.40%	29.00%	17.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	177.66%	0.00%	0.00%	0.00%	0.00%	0.00%	123.62%	118.57%	113.59%	11.09%

Frequently Asked Questions About Corcept Therapeutics' Financials

When does Corcept Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Corcept Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Corcept Therapeutics' net income changed over the last 9 years?

Corcept Therapeutics' net income appears to be on an upward trend, with a most recent value of $141.21 million in 2024, falling from -$6.41 million in 2015. The previous period was $106.14 million in 2023.

What is Corcept Therapeutics's operating income?

Corcept Therapeutics's total operating income in 2024 was $136.95 million, based on the following breakdown:

Total Gross Profit: $664.16 million
Total Operating Expenses: $527.21 million

How has Corcept Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Corcept Therapeutics' total revenue changed from $50.29 million in 2015 to $675.04 million in 2024, a change of 1,242.4%.

How much debt does Corcept Therapeutics have?

Corcept Therapeutics' total liabilities were at $160.96 million at the end of 2024, a 40.2% increase from 2023, and a 381.9% increase since 2015.

How much cash does Corcept Therapeutics have?

In the past 9 years, Corcept Therapeutics' cash and equivalents has ranged from $31.06 million in 2017 to $135.55 million in 2023, and is currently $127.67 million as of their latest financial filing in 2024.

How has Corcept Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Corcept Therapeutics' book value per share changed from 0.17 in 2015 to 6.49 in 2024, a change of 3,713.2%.

Remove Ads

Related Companies

This page (NASDAQ:CORT) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Financials

Frequently Asked Questions About Corcept Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Financials

Annual Income Statements for Corcept Therapeutics

Quarterly Income Statements for Corcept Therapeutics

Annual Cash Flow Statements for Corcept Therapeutics

Quarterly Cash Flow Statements for Corcept Therapeutics

Annual Balance Sheets for Corcept Therapeutics

Quarterly Balance Sheets for Corcept Therapeutics

Annual Metrics and Ratios for Corcept Therapeutics

Quarterly Metrics and Ratios for Corcept Therapeutics

Frequently Asked Questions About Corcept Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools